



The Story of Successful Drugs and Recent FDA-Approved Molecules

Collection Editors:

Dr. Maria Emília De Sousa

Dr. Jean Jacques Vanden Eynde

Prof. Dr. Klaus Kopka

Dr. Annie Mayence

Prof. Dr. Joachim Jose

Prof. Dr. Guangshun Wang

Message from the Collection Editors

Dear Colleagues,

Each year, the FDA approves dozens of novel small molecules and biological derivatives as new therapeutic compounds, thus demonstrating the vigor of the pharmaceutical industry and associated research groups. Small molecules are the most represented entities among the approvals, but there are also an increasing number of antibodies and oligonucleotides on the medical market. Interestingly, there is a growing interest in the development of orphan drugs and the treatment of orphan diseases and rare diseases.

We invite readers of this Topical Collection to explore a range of short but comprehensive and updated reviews on drugs attracting particular attention owing to their success and to their compounds being (recently) approved by the FDA.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com